JP2017088621A - Hyperglycemia inhibiting composition - Google Patents

Abstract

PROBLEM TO BE SOLVED: To provide a hyperglycemia inhibiting composition having dramatically improved hyperglycemia inhibitory action.SOLUTION: A hyperglycemia inhibiting composition comprises indigestible dextrin, and at least one plant material selected from the group consisting of lemongrass, rose hip, and mulberry as an active ingredient.SELECTED DRAWING: Figure 1

Description

  TECHNICAL FIELD The present invention relates to a blood sugar level increase inhibiting composition, and in particular, relates to a blood sugar level rise inhibiting composition comprising an indigestible dextrin and a specific plant material as active ingredients.

  Indigestible dextrins are known to have various functions for adjusting the body condition, and as one of them, an action to suppress an increase in blood glucose level is known. However, it cannot be said that the single effect is sufficient.

  On the other hand, as for the function of indigestible dextrin, for example, an IgA secretion promoter containing indigestible dextrin as an active ingredient (see Patent Document 1) or for patients with renal failure having indigestible dextrin as an active ingredient A blood cresol reducing agent (see Patent Document 2) has been proposed.

JP 2014-152125 A JP 2014-148467 A

  The subject of this invention is providing the blood glucose level rise inhibitory composition which the blood glucose level rise inhibitory action improved greatly.

  The present inventors have conducted extensive research and research on the inhibitory action of indigestible dextrin on the increase in blood sugar level, and by combining a specific plant material with indigestible dextrin, the action of suppressing the increase in blood sugar level can be dramatically improved. The present invention has been completed. That is, by combining a plant material with little or no blood glucose level inhibitory action with an indigestible dextrin, the action to suppress the blood sugar level rises dramatically compared to the case of indigestible dextrin alone. I found that it can be improved.

  That is, the present invention comprises an indigestible dextrin and at least one plant material selected from the group consisting of lavender, lemongrass, dokudami, rosehip, and mulberry (mulberry) as active ingredients. The present invention relates to a composition for suppressing blood sugar level elevation.

  The blood sugar level elevation inhibiting composition of the present invention may be obtained by adding an active ingredient.

In the blood sugar level elevation inhibiting composition of the present invention, the blending mass ratio of the indigestible dextrin and other active ingredients is preferably in the range of 0.5: 1 to 70: 1.
Moreover, it is preferable that the blood glucose level rise inhibitory composition of this invention is a tablet, a capsule, a powder agent, a granule, or a liquid agent.

  In addition, the present invention relates to a blood glucose level elevation suppressing method (excluding medical practice) characterized by ingesting the blood glucose level elevation inhibiting composition of the present invention.

  According to the blood sugar level elevation inhibiting composition of the present invention, the blood sugar level elevation inhibiting action can be dramatically improved as compared with the case of the indigestible dextrin alone.

It is a figure which shows the glucose level which passed through the secreted monolayer after absorption to the Caco-2 monolayer film at the time of applying the blood sugar level rise inhibitory composition of this invention, and is a lavender as a plant material with indigestible dextrin The result at the time of using lemon grass is shown. It is a figure which shows the glucose concentration secreted after absorption in the Caco-2 monolayer film at the time of applying the blood sugar level rise inhibitory composition of this invention, and is a case where dokudami is used as a plant material with indigestible dextrin Results are shown. It is a figure which shows the glucose concentration secreted after absorption to the Caco-2 monolayer film at the time of applying the blood sugar level rise inhibitory composition of this invention, and uses rosehip and mulberry as a plant material with indigestible dextrin The result is shown.

  The blood sugar level elevation inhibiting composition of the present invention is at least one plant material selected from the group consisting of indigestible dextrin and lavender, lemongrass, dokudami, rosehip, and mulberry (hereinafter sometimes referred to as other components). ) As an active ingredient.

[Indigestible dextrin]
The indigestible dextrin as an active ingredient of the composition for suppressing an increase in blood sugar level of the present invention is an indigestible polysaccharide that is not easily hydrolyzed by a human digestive enzyme (amylase). For example, starch is hydrolyzed by heating. Thereafter, it can be obtained by hydrolysis with amylase and purification of a component that is difficult to hydrolyze. This indigestible dextrin is commercially available in the form of powder, fine granules, granules and the like, and these commercially available products can be used. Moreover, since indigestible dextrin is water-soluble, you may use the thing of the form of aqueous solution.

[Other ingredients]
The plant material may be any part of the plant such as leaves, stems, roots, flowers, fruits, trunks, branches, etc. In addition to the plant material itself (including dried products), its pulverized product, juice, extraction Processed plant material such as products can be used. Examples of the pulverized product include powder and granules. The juice or extract may be liquid, but can also be used as a paste or dry powder. The extract can be obtained by extraction using an appropriate solvent. As the solvent, for example, water (hot water, hot water), ethanol, hydrous ethanol can be used.

  The lavender is a plant belonging to the family Lamiaceae, and a flower is preferable as a site used in the present invention. Lemongrass is a plant belonging to the family Gramineae, and leaves are preferred as the site used in the present invention. Dokudami is a plant belonging to the genus Dokudami family, and as the site used in the present invention, stems and leaves (ground part) are preferable. Rosehip is a plant belonging to the family Rosaceae, and a fruit is preferable as a site used in the present invention. Mulberry is a plant belonging to the genus Mulberry family, and a leaf is preferable as a site used in the present invention.

  It is preferable that the blood sugar level increase inhibitory composition of the present invention is a blood sugar level increase inhibitor used for suppressing blood sugar level increase. Such a blood sugar level increase inhibitor is particularly limited as long as it contains an indigestible dextrin and a predetermined plant material and can be distinguished from other products as a product in terms of being used for suppressing blood sugar level increase. For example, the display of the fact that any of the main body, packaging, instructions, and promotional material of the product according to the present invention has a function of suppressing the increase in blood glucose level is included in the scope of the present invention. For example, so-called health foods such as pharmaceuticals (including quasi-drugs), functional foods for which the indication of efficacy has been approved by specified organizations such as foods for specified health use, functional nutritional foods, functional labeling foods, feeds, etc. Can be mentioned. In so-called health foods, "for those who are starting to worry about blood sugar levels", "for those who are concerned about blood sugar levels (after meals)", "to moderate the increase in blood sugar levels", "to absorb sugar For example, those that display “smooth”, “suppress blood glucose level”, and the like can be exemplified. These health foods may be taken separately from the meal, but are preferably taken at the time of the meal. For example, it is preferably taken between 1 hour before the meal and 1 hour after the meal. It is more preferable to take between 5 hours and 0.5 hours after meal, and it is more preferable to take from 0.5 hours before meal to the start of meal or during meal.

  Examples of the form of the blood sugar level elevation inhibiting composition of the present invention include tablets, capsules, powders, granules, liquids, granules, rods, plates, blocks, solids, and rounds. , Paste agents, cream agents, caplet agents, gel agents, chewable agents, stick agents and the like. Among these, the forms of tablets, capsules, powders, granules, and liquids are particularly preferable. Specifically, supplements, container-packed beverages filled in PET bottles, cans, bottles, etc., instant powder beverages and instant granule beverages for dissolving and drinking in water (hot water), milk, fruit juice, green juice, etc. Can be illustrated. These are preferable in that they can be easily taken at the time of eating and the like, and can enhance palatability.

  The contents of the indigestible dextrin and other components (active ingredients) in the blood sugar level elevation inhibiting composition of the present invention may be appropriately contained within the range where the effects are exerted.

  Generally, when the blood sugar level elevation inhibiting composition of the present invention is a pharmaceutical product or a supplement (tablet, capsule), the active ingredient should be contained in an amount of 0.01 to 100% by mass in terms of dry mass. Is more preferable, 0.1 to 85 mass% is more preferable, and 0.5 to 70 mass% is further more preferable.

  When the blood sugar level elevation inhibiting composition of the present invention is a packaged beverage (liquid), the active ingredient is preferably contained in an amount of 0.1 to 10% by mass in terms of dry mass, and 0.3 to It is more preferable that 6 mass% is contained, and it is further more preferable that 0.5-4 mass% is contained.

  In addition, when the blood sugar level elevation inhibiting composition of the present invention is an instant powder beverage (powder) or an instant granule beverage (granule), the active ingredient is contained in an amount of 10 to 100% by mass in terms of dry mass. Preferably, it is contained in an amount of 50 to 100% by mass, more preferably 80 to 100% by mass.

  In order to exhibit the effect of the present invention particularly effectively, it is preferable that the active ingredient is contained in an amount of 80% by mass or more of the whole blood sugar level elevation inhibiting composition of the present invention (excluding moisture) in terms of dry mass, More preferably, it is contained more than 95% by mass, more preferably more than 95% by mass, and particularly preferably 100% by mass.

  There is no particular limitation on the intake of the blood sugar level elevation inhibiting composition of the present invention, but from the viewpoint of more prominently exerting the effects of the present invention, the intake of the active ingredient per day is 500 mg / day or more. It is preferable to take 1 g / day or more, more preferably 2 g / day or more, more preferably 4 g / day or more. Particularly preferred.

  The composition for suppressing an increase in blood sugar level of the present invention is accommodated in one container or divided into a plurality of containers such as 2 to 3 so that the daily intake becomes the above-mentioned intake. Can do.

  In addition, the blood sugar level elevation-suppressing composition of the present invention may be taken separately from meals, but since it can particularly effectively suppress a transient increase in blood sugar level after meals, it is taken during meals. Preferably, for example, it is taken between 1 hour before meal and 1 hour after meal, more preferably taken between 0.5 hour before meal and 0.5 hour after meal, More preferably, it is taken from 5 hours to the beginning of the meal or during the meal.

  The blending mass ratio of the indigestible dextrin and other components is preferably in the range of 0.5: 1 to 70: 1 and in the range of 0.75: 1 to 60: 1 in terms of dry mass. Is more preferably in the range of 1: 1 to 60: 1, and particularly preferably in the range of 1: 1 to 50: 1. The effects of the present invention can be more effectively exhibited when the blending ratio of the indigestible dextrin and other components is within the above range.

  The blood sugar level elevation inhibitory composition of the present invention can be produced by a known formulation method by adding components other than the active ingredient acceptable for oral use, if necessary.

  Moreover, as the blood sugar level elevation inhibiting composition of the present invention, in addition to the blood sugar level elevation inhibiting composition containing an active ingredient, a blood sugar level elevation inhibiting composition obtained by adding an active ingredient to a food For example, foods with an increased content of the active ingredient of the present invention compared to normal foods (including natural foods) and foods that do not normally contain the active ingredient of the present invention. On the other hand, the foodstuff which added the active ingredient can be mentioned. Moreover, as a blood sugar level rise inhibitory composition of this invention, from the point by which the effect of this invention is exhibited more effectively, carbohydrate content is 10 mass% or more, Preferably it is 20 mass% or more high-sugar food. On the other hand, a high sugar food that suppresses an increase in blood glucose level obtained by adding an active ingredient is preferred. For the addition of the active ingredients, the respective ingredients may be added separately, may be added simultaneously, or may be added together with other ingredients other than the active ingredients.

  Examples of the food for suppressing blood sugar level elevation of the present invention include, for example, carbonated drinks, nutrition drinks, fruit drinks, lactic acid drinks, smoothies, green juice drinks; ice cream, ice sherbet, shaved ice and other frozen desserts; buckwheat, udon, harusame, Chinese noodles, instant noodles and other noodles; rice cakes, candy, gum, chocolate, tablet confectionery, snack confectionery, biscuits, jelly, jam, cream, baked confectionery, bread confectionery, etc .; fish and livestock processing such as kamaboko, ham, sausage Foods; Dairy products such as processed milk, fermented milk, yogurt; salad oil, tempura oil, margarine, mayonnaise, shortening, whipped cream, dressing and other fats and processed foods; seasonings such as sauces, soy sauce; curry, stew, parent and child Rice cakes, rice cakes, miscellaneous cooking, Chinese rice cakes, bonito, tempura, beef rice bowl, hayashi rice, omelet rice, oden, ma Dorff, dumplings, Shumai, hamburger, meatballs, various sources, such as retort pouch foods such as various types of soup can be mentioned.

  The method for suppressing blood glucose level elevation according to the present invention is characterized by ingesting the composition for inhibiting blood glucose level elevation according to the present invention described above, but does not include medical practice. The composition for suppressing an increase in blood sugar level of the present invention may be ingested separately from a meal, but can be ingested at the time of a meal because it can particularly effectively suppress a transient increase in blood sugar level after a meal. Preferably, for example, it is preferably taken between 1 hour before meal and 1 hour after meal, more preferably taken between 0.5 hour before meal and 0.5 hour after meal, More preferably, it is taken from the time until the start of the meal or during the meal. Examples of the method of the present invention include a method for suppressing an increase in blood glucose level by providing the composition for suppressing an increase in blood glucose level of the present invention together with a high sugar food at a restaurant such as a restaurant.

Hereinafter, the present invention is described based on examples.
[Example 1]
The suppression of increase in blood glucose level was evaluated by the human colon cancer-derived cell Caco-2 monolayer absorption and secretion test. Caco-2 cells are known to differentiate into intestinal epithelium like by culture, and the intestinal absorbability can be evaluated by measuring the amount of absorbed and secreted substances with respect to the Caco-2 cell membrane.

1. Preparation of sample D-glucose and a test substance (indigestible dextrin alone, indigestible dextrin + other components shown in Table 1) were added to PBS (+) buffer. The final concentration of D-glucose was 25 mM. In the case of the indigestible dextrin alone, the indigestible dextrin was 500 μg / mL, and in the case of the indigestible dextrin + other components, the indigestible dextrin was 500 μg / mL and the other components were 1000 μg / mL.

2. Caco-2 Cell Membrane Absorption and Secretion Test 100 μL of the sample was added to an insert well of a Caco-2 monolayer membrane, and held in a 37 ° C., 5% CO ₂ incubator. After 4 hours, a solution on the basement membrane side was collected, 10 μL of this solution was collected, and the glucose concentration was measured with a Wako kit (glucose CII-Test Wako).

  The results are shown in Table 1 and FIGS. In each graph in the figure, “−” indicates no addition and “+” indicates a single addition of 500 μg / mL indigestible dextrin for the control (difficulty). Moreover, about what displayed the other component, "-+" shows the single addition of 1000 microgram / mL other components, and "++" shows 500 microgram / mL indigestible dextrin +1000 microgram / mL other components addition.

For the indigestible dextrin, commercially available indigestible dextrin powder was used.
For lavender, lemongrass, and rosehip, pulverized products obtained by pulverizing commercially available raw materials for 20 seconds × 7 times with a bead shocker (rotation speed: 2,300 rpm) were used. For Dokudami, commercially available powdery raw materials were used. For mulberry and mugwort, dry ground powder of fresh leaves was used.

  As shown in Table 1 and FIG. 1 to FIG. 3, by combining the indigestible dextrin and the specific plant material of the present invention, the amount of glucose secreted after absorption into the Caco-2 monolayer is synergistic. Declined. Therefore, it can be seen that the increase in blood glucose level can be effectively suppressed according to the blood sugar level increase suppressing composition of the present invention.

[Example 2] (Manufacture of tablets)
Each component was mixed in the ratio shown below, and tableting was performed with a tableting machine.

Formulation composition Composition (mg)
Indigestible dextrin 125
Lavender powder 100
Excipient 35
Vitamins 15
Citric anhydride 15

  For example, by taking about 3 to 10 tablets per day (ingestion amount of active ingredient 675 to 2250 mg per day), it is expected that an effect of suppressing an increase in blood glucose level can be obtained.

[Example 3] (Manufacture of capsules)
15 parts by weight of indigestible dextrin was mixed with 1 part by weight of lemongrass powder, and granulated according to a conventional method. The capsule was filled with 250 mg of the granule to prepare a capsule.

  For example, by taking 2 capsules per day (intake amount of active ingredient 500 mg per day), it is expected that an effect of suppressing an increase in blood glucose level can be obtained.

[Example 4] (Production of granules)
15 parts by weight of indigestible dextrin was mixed with 1 part by weight of rosehip to prepare granules according to a conventional method, and 800 mg of the granules were packaged in an aluminum stick.

  For example, it is expected that the effect of suppressing an increase in blood glucose level can be obtained by ingesting 3 bags of this granule per day (intake of active ingredient 2400 mg per day).

[Example 5] (Manufacture of solution)
Fill a plastic bottle with 5 parts by weight of young barley powder, 2 parts by weight of kale, 1 part by weight of Dokudami extract, 1 part by weight of mulberry extract, 15 parts by weight of indigestible dextrin, vitamin C and 500 ml of water. Then, a liquid preparation was produced.

  Since the blood sugar level elevation suppressing composition of the present invention has an effect of suppressing an increase in blood sugar level, the industrial utility is high.

Claims (2)

  A food composition for suppressing an increase in blood glucose level, comprising an indigestible dextrin and at least one plant material selected from the group consisting of lemongrass, rosehip and mulberry. The food composition for suppressing an increase in blood glucose level according to claim 1, wherein the food composition is a powder, granule, or liquid.